The human immunodeficiency virus (HIV) is a disease worldwide with the increasing number of cases globally. Initially, HIV colliaiopati was often observed among these patients but has become rare after three decades due to the availability of new care choices and strong antiretroviral drugs. As a result, the incident now suggests drug resistance or the development of the disease. The relationship between Cholaghiocarcinoma and HIV is still unclear. We report cases of patients with high-grade dysplasia from Choledochus ducts and uncontrolled diseases treated with strong antivirus agents and dilated bile tract.

Learning points: HIV Choligiopathy must be remembered in HIV-positive patients even if they receive combination (train) antiretroviral therapy; Endoscopy Retrograde Choliaiopancreatography can provide symptomatic assistance. After HIV Chorangiopathy is detected, follow-up for Cholangiocarcinoma is needed. Corrected infections can cause choliaiocarcinoma in HIV-positive patients.

The decrease in the incidence of acute rejection without increasing the incidence of cytomegalovirus (CMV) infection in recipients of kidney transplants that accept the anti-thymocyte globulin (RATG) rabbit without prophylactic CMV

Induction therapy with the anti-thymocyte globulin (RATG) rabbit in recipients of low-risk ktridal transplants (KTR) remains controversial, given the increased risk of cytomegalovirus (CMV) infection. This natural experiment compares the clinical results of 12 months in low-risk KTR without CMV prophylaxis (Jan / 3/13-Sep / 16/15) accepting without induction or a single dose of 3mg / kg. We use logistic regression to characterize the pending graft function (DGF), negative binomials to characterize the length of hospitalization of hospitals (LOS) and Cox regression to characterize acute rejection (AR), CMV infection, mistrident of grafting, death and readmission.

The recipient received 3mg / kg Ratg had a risk of 81% lower than AR (AHR 0.14 0.190.25, p <0.001) but there was no increase in hospital admission due to infection (0.911.21, p = 0.5). There is no relationship between 3 mg / kg infection / CMV disease (AHR 0.86 1,101.40, p = 0.5), even when analysis is grouped based on the positive CMV serostatatus (AHR 0.94 1.25 1.65, p = 0, 15) and negative (AHR 0.28 0.57 1.16, p = 0.1). There is no relationship between 3MG / kg Ratg and mortality (AHR 0.51 1,253.08, p = 0.6), loss of grafts (AHR 0.34 0.731.55, p = 0.4). Among the low-risk ktr that does not accept the pharmacological prophylaxis of CMV, induction of 3mg / kg Ratg is associated with a significant reduction in the incidence of AR without an increased risk of CMV infection, regardless of the pre-transplant receiver CMV serostatus.

Lesions such as Degos as a skin manifestation of Cytomegalovirus infection: rare and serious complications in patients with drug induced hypersensitivity syndrome

Cytomegalovirus causes a myriad of clinical features, potentially influencing any organ system, significantly increases morbidity and even mortality. Vascular endothelial cell infections by CyTomeGalovirus have been involved in the development of Vasculopathy, perhaps accounting for clinical relations between Cytomegalovirus and vascular thrombosis. Unlike the involvement of visceral organs, cytomegalovirus skin manifestations varies and are rarely explained. Papulosis of malignant atrophy, which is commonly known as a Degos disease, is an unusual arteriopathic ship with a patognomonic clinical appearance from the middle porcelain-white papules surrounded by erythema Telangiectatic.

Like the arterial occlusive process, Degos may be idiopathic or secondary to autoimmune disorders or viral infections. All in all, presentations such as Degos related to Cytomegalovirus have never been explained. This report illustrates cases where disseminated cytomegalovirus disease is developed 4 weeks after the emergence of hypersensitivity syndrome induced by drugs with skin lesions such as prominent degos. Our case highlights a rare example of lesions such as Degos that occur because of cytomegalovirus disease and emphasizes the importance of early recognition of skin eruption characteristics as a diagnostic instrument that leads to the management of this life-threatening infection.

Cytomegalovirus pancreatitis in immunocompetent patients

Cytomegalovirus (CMV) is a DNA virus whose double strand, which infects most of the adult population. In immunocompetent patients, usually asymptomatic or manifest as symptoms of mild flu and self-limit, while in immunocompromised patients, CMV can cause significant disease. Here we report cases of unusual CMV pancreatitis in the 75-year-old woman’s immunocompetent. Patients develop severe significant pancreatic necrosis that failed non-operative management, and ultimately underwent the Pancreatic Necrosectomy. Then, he developed three spontaneous gastric perforations.

The first two perforations were managed operatively, but after the third perforation family decided not to undergo other operations. The diagnosis of CMV pancreatitis is based on pancreatic histopathology and confirms with a rapid response to Ganciclovir. The patient immediately began at Ganciclovir Intravenous (IV) which resulted in clinical recovery and he remained without symptoms of more than one year post op. This is a rare case of CMV pancreatitis with gastric perforation in immunocompetent patients. The level of suspicion is high and the right maintenance is important for such a clinical scenario.

Microvascular and structural abnormalities extralesional in cytomegalovirus retinitis

To evaluate extraesional microvascular and structural changes from the macula using Optical Coherence Tomography Angiography (Octa) and Structural October in the Citomegalovirus Retinitis (CMVR). A CMVR patient observational study was conducted. Complete ophthalmic examination, serial color fundus fundus, structural October and Octa are carried out at the beginning and follow-up visits up to 12 months. The structural OCT was analyzed to evaluate the macular area inside, bordering and exceed CMVR lesions.

Plexus extraledional retina capillaries from maculas are evaluated with October angiography and compared to fellow eyes that are not affected. Thirteen eyes from 13 registered patients. On the basis, the macular area without CMVR lesions showed a decrease in ship density (VD) of both superficial (p = 0,0002) and inside (p <0.0001) the retinal capillary plexus in the eye with CMVR compared to the area of ​​the macular not affected by fellow eyes that are not affected. The decrease in VD survives through the follow-up period of up to 12 months after adjusting the degree of vitreous fog.

anti- TTC39B antibody
FNab09086	FN Test	100µg	EUR 658.5
Description: Antibody raised against TTC39B

TTC39B Antibody, HRP conjugated
1-CSB-PA713348LB01HU	Cusabio	EUR 380.40 EUR 402.00	100ul 50ul
Description: A polyclonal antibody against TTC39B. Recognizes TTC39B from Human. This antibody is HRP conjugated. Tested in the following application: ELISA

TTC39B Antibody, FITC conjugated
1-CSB-PA713348LC01HU	Cusabio	EUR 380.40 EUR 402.00	100ul 50ul
Description: A polyclonal antibody against TTC39B. Recognizes TTC39B from Human. This antibody is FITC conjugated. Tested in the following application: ELISA

TTC39B Antibody, Biotin conjugated
1-CSB-PA713348LD01HU	Cusabio	EUR 380.40 EUR 402.00	100ul 50ul
Description: A polyclonal antibody against TTC39B. Recognizes TTC39B from Human. This antibody is Biotin conjugated. Tested in the following application: ELISA

Human TTC39B shRNA Plasmid
20-abx965852	Abbexa	EUR 961.20 EUR 1345.20	150 µg 300 µg

Mouse TTC39B shRNA Plasmid
20-abx977074	Abbexa	EUR 961.20 EUR 1345.20	150 µg 300 µg

Rat TTC39B shRNA Plasmid
20-abx988909	Abbexa	EUR 961.20 EUR 1345.20	150 µg 300 µg

TTC39B ELISA KIT|Human
EF003927	Lifescience Market	96 Tests	EUR 826.8

TTC39B Recombinant Protein (Human)
RP033328	ABM	100 ug	Ask for price

TTC39B Recombinant Protein (Rat)
RP235163	ABM	100 ug	Ask for price

TTC39B Recombinant Protein (Mouse)
RP182057	ABM	100 ug	Ask for price

Polyclonal TTC39B Antibody (C-term)
APR03519G	Leading Biology	0.1ml	EUR 580.8
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human TTC39B (C-term). This antibody is tested and proven to work in the following applications:

Ttc39b ORF Vector (Rat) (pORF)
ORF078389	ABM	1.0 ug DNA	EUR 607.2

Ttc39b ORF Vector (Mouse) (pORF)
ORF060687	ABM	1.0 ug DNA	EUR 607.2

TTC39B ORF Vector (Human) (pORF)
ORF011110	ABM	1.0 ug DNA	EUR 114

Tetratricopeptide Repeat Protein 39B (TTC39B) Antibody
abx145789-100ug	Abbexa	100 ug	EUR 469.2

Tetratricopeptide Repeat Protein 39B (TTC39B) Antibody
abx026040-400ul	Abbexa	400 ul	EUR 627.6

Tetratricopeptide Repeat Protein 39B (TTC39B) Antibody
abx026040-80l	Abbexa	80 µl	EUR 343.2

Tetratricopeptide Repeat Protein 39B (TTC39B) Antibody
abx239086-100ug	Abbexa	100 ug	EUR 610.8

Ttc39b sgRNA CRISPR Lentivector set (Rat)
K6591501	ABM	3 x 1.0 ug	EUR 406.8

Ttc39b sgRNA CRISPR Lentivector set (Mouse)
K4952201	ABM	3 x 1.0 ug	EUR 406.8

TTC39B sgRNA CRISPR Lentivector set (Human)
K2551101	ABM	3 x 1.0 ug	EUR 406.8

HNRRabbit pAb Rabbit pAb
A17497-100ul	Abclonal	100 ul	EUR 369.6

HNRRabbit pAb Rabbit pAb
A17497-200ul	Abclonal	200 ul	EUR 550.8

HNRRabbit pAb Rabbit pAb
A17497-20ul	Abclonal	20 ul	EUR 219.6

HNRRabbit pAb Rabbit pAb
A17497-50ul	Abclonal	50 ul	EUR 267.6

Rabbit pAbPC1 Rabbit pAb
A14872-100ul	Abclonal	100 ul	EUR 369.6

Rabbit pAbPC1 Rabbit pAb
A14872-200ul	Abclonal	200 ul	EUR 550.8

Rabbit pAbPC1 Rabbit pAb
A14872-20ul	Abclonal	20 ul	EUR 219.6

Rabbit pAbPC1 Rabbit pAb
A14872-50ul	Abclonal	50 ul	EUR 267.6

Rabbit pAbPC5 Rabbit pAb
A9997-100ul	Abclonal	100 ul	EUR 369.6

Rabbit pAbPC5 Rabbit pAb
A9997-200ul	Abclonal	200 ul	EUR 550.8

Rabbit pAbPC5 Rabbit pAb
A9997-20ul	Abclonal	20 ul	EUR 219.6

Rabbit pAbPC5 Rabbit pAb
A9997-50ul	Abclonal	50 ul	EUR 267.6

Rabbit pAbPC4 Rabbit pAb
A5948-100ul	Abclonal	100 ul	EUR 369.6

Rabbit pAbPC4 Rabbit pAb
A5948-200ul	Abclonal	200 ul	EUR 550.8

Rabbit pAbPC4 Rabbit pAb
A5948-20ul	Abclonal	20 ul	EUR 219.6

Rabbit pAbPC4 Rabbit pAb
A5948-50ul	Abclonal	50 ul	EUR 267.6

Rabbit pAbPN1 Rabbit pAb
A6041-100ul	Abclonal	100 ul	EUR 369.6

Rabbit pAbPN1 Rabbit pAb
A6041-200ul	Abclonal	200 ul	EUR 550.8

Rabbit pAbPN1 Rabbit pAb
A6041-20ul	Abclonal	20 ul	EUR 219.6

Rabbit pAbPN1 Rabbit pAb
A6041-50ul	Abclonal	50 ul	EUR 267.6

Rabbit pAbPC3 Rabbit pAb
A18370-100ul	Abclonal	100 ul	EUR 369.6

Rabbit pAbPC3 Rabbit pAb
A18370-200ul	Abclonal	200 ul	EUR 550.8

Rabbit pAbPC3 Rabbit pAb
A18370-20ul	Abclonal	20 ul	EUR 219.6

Rabbit pAbPC3 Rabbit pAb
A18370-50ul	Abclonal	50 ul	EUR 267.6

Ttc39b sgRNA CRISPR Lentivector (Rat) (Target 1)
K6591502	ABM	1.0 ug DNA	EUR 184.8

Ttc39b sgRNA CRISPR Lentivector (Rat) (Target 2)
K6591503	ABM	1.0 ug DNA	EUR 184.8

Ttc39b sgRNA CRISPR Lentivector (Rat) (Target 3)
K6591504	ABM	1.0 ug DNA	EUR 184.8

Ttc39b sgRNA CRISPR Lentivector (Mouse) (Target 1)
K4952202	ABM	1.0 ug DNA	EUR 184.8

Ttc39b sgRNA CRISPR Lentivector (Mouse) (Target 2)
K4952203	ABM	1.0 ug DNA	EUR 184.8

Ttc39b sgRNA CRISPR Lentivector (Mouse) (Target 3)
K4952204	ABM	1.0 ug DNA	EUR 184.8

TTC39B sgRNA CRISPR Lentivector (Human) (Target 1)
K2551102	ABM	1.0 ug DNA	EUR 184.8

TTC39B sgRNA CRISPR Lentivector (Human) (Target 2)
K2551103	ABM	1.0 ug DNA	EUR 184.8

TTC39B sgRNA CRISPR Lentivector (Human) (Target 3)
K2551104	ABM	1.0 ug DNA	EUR 184.8

TTC39B Protein Vector (Human) (pPB-C-His)
PV044437	ABM	500 ng	EUR 394.8

TTC39B Protein Vector (Human) (pPB-N-His)
PV044438	ABM	500 ng	EUR 394.8

TTC39B Protein Vector (Human) (pPM-C-HA)
PV044439	ABM	500 ng	EUR 394.8

TTC39B Protein Vector (Human) (pPM-C-His)
PV044440	ABM	500 ng	EUR 394.8

TTC39B 3'UTR GFP Stable Cell Line
TU077428	ABM	1.0 ml	EUR 1672.8

Ttc39b 3'UTR GFP Stable Cell Line
TU272613	ABM	1.0 ml	Ask for price

Ttc39b 3'UTR GFP Stable Cell Line
TU171312	ABM	1.0 ml	Ask for price

Ttc39b 3'UTR Luciferase Stable Cell Line
TU222613	ABM	1.0 ml	Ask for price

TTC39B Protein Vector (Rat) (pPB-C-His)
PV313554	ABM	500 ng	EUR 723.6

TTC39B Protein Vector (Rat) (pPB-N-His)
PV313555	ABM	500 ng	EUR 723.6

TTC39B Protein Vector (Rat) (pPM-C-HA)
PV313556	ABM	500 ng	EUR 723.6

TTC39B Protein Vector (Rat) (pPM-C-His)
PV313557	ABM	500 ng	EUR 723.6

TTC39B Protein Vector (Mouse) (pPB-C-His)
PV242746	ABM	500 ng	EUR 723.6

TTC39B Protein Vector (Mouse) (pPB-N-His)
PV242747	ABM	500 ng	EUR 723.6

TTC39B Protein Vector (Mouse) (pPM-C-HA)
PV242748	ABM	500 ng	EUR 723.6

TTC39B Protein Vector (Mouse) (pPM-C-His)
PV242749	ABM	500 ng	EUR 723.6

Ttc39b 3'UTR Luciferase Stable Cell Line
TU121312	ABM	1.0 ml	Ask for price

TTC39B 3'UTR Luciferase Stable Cell Line
TU027428	ABM	1.0 ml	EUR 1672.8

Elk (Ser383) ? Rabbit* Polyclonal Antibody
ABP-PAB-21010	Allele Biotech	100 ug	Ask for price

PPIA Rabbit pAb
A0113-100ul	Abclonal	100 ul	EUR 369.6

PPIA Rabbit pAb
A0113-200ul	Abclonal	200 ul	EUR 550.8

PPIA Rabbit pAb
A0113-20ul	Abclonal	20 ul	Ask for price

PPIA Rabbit pAb
A0113-50ul	Abclonal	50 ul	Ask for price

EMD Rabbit pAb
A0116-100ul	Abclonal	100 ul	EUR 369.6

EMD Rabbit pAb
A0116-200ul	Abclonal	200 ul	EUR 550.8

EMD Rabbit pAb
A0116-20ul	Abclonal	20 ul	Ask for price

EMD Rabbit pAb
A0116-50ul	Abclonal	50 ul	Ask for price

PDIA3 Rabbit pAb
A0117-100ul	Abclonal	100 ul	EUR 369.6

PDIA3 Rabbit pAb
A0117-200ul	Abclonal	200 ul	EUR 550.8

PDIA3 Rabbit pAb
A0117-20ul	Abclonal	20 ul	Ask for price

PDIA3 Rabbit pAb
A0117-50ul	Abclonal	50 ul	Ask for price

INPP5D Rabbit pAb
A0122-100ul	Abclonal	100 ul	EUR 369.6

INPP5D Rabbit pAb
A0122-200ul	Abclonal	200 ul	EUR 550.8

INPP5D Rabbit pAb
A0122-20ul	Abclonal	20 ul	EUR 219.6

INPP5D Rabbit pAb
A0122-50ul	Abclonal	50 ul	EUR 267.6

KRT17 Rabbit pAb
A0123-100ul	Abclonal	100 ul	EUR 369.6

KRT17 Rabbit pAb
A0123-200ul	Abclonal	200 ul	EUR 550.8

KRT17 Rabbit pAb
A0123-20ul	Abclonal	20 ul	EUR 219.6

KRT17 Rabbit pAb
A0123-50ul	Abclonal	50 ul	EUR 267.6

PBX1 Rabbit pAb
A0124-100ul	Abclonal	100 ul	EUR 369.6

PBX1 Rabbit pAb
A0124-200ul	Abclonal	200 ul	EUR 550.8

PBX1 Rabbit pAb
A0124-20ul	Abclonal	20 ul	EUR 219.6

PBX1 Rabbit pAb
A0124-50ul	Abclonal	50 ul	EUR 267.6

NCSTN Rabbit pAb
A0128-100ul	Abclonal	100 ul	EUR 369.6

NCSTN Rabbit pAb
A0128-200ul	Abclonal	200 ul	EUR 550.8

NCSTN Rabbit pAb
A0128-20ul	Abclonal	20 ul	EUR 219.6

NCSTN Rabbit pAb
A0128-50ul	Abclonal	50 ul	EUR 267.6

FEN1 Rabbit pAb
A0129-100ul	Abclonal	100 ul	EUR 369.6

FEN1 Rabbit pAb
A0129-200ul	Abclonal	200 ul	EUR 550.8

FEN1 Rabbit pAb
A0129-20ul	Abclonal	20 ul	Ask for price

FEN1 Rabbit pAb
A0129-50ul	Abclonal	50 ul	Ask for price

LRP5 Rabbit pAb
A0130-100ul	Abclonal	100 ul	EUR 369.6

LRP5 Rabbit pAb
A0130-200ul	Abclonal	200 ul	EUR 550.8

LRP5 Rabbit pAb
A0130-20ul	Abclonal	20 ul	EUR 219.6

LRP5 Rabbit pAb
A0130-50ul	Abclonal	50 ul	EUR 267.6

CBX5 Rabbit pAb
A0132-100ul	Abclonal	100 ul	EUR 369.6

CBX5 Rabbit pAb
A0132-200ul	Abclonal	200 ul	EUR 550.8

CBX5 Rabbit pAb
A0132-20ul	Abclonal	20 ul	Ask for price

CBX5 Rabbit pAb
A0132-50ul	Abclonal	50 ul	Ask for price

BCL2A1 Rabbit pAb
A0134-100ul	Abclonal	100 ul	EUR 369.6

BCL2A1 Rabbit pAb
A0134-200ul	Abclonal	200 ul	EUR 550.8

BCL2A1 Rabbit pAb
A0134-20ul	Abclonal	20 ul	Ask for price

BCL2A1 Rabbit pAb
A0134-50ul	Abclonal	50 ul	Ask for price

TERF1 Rabbit pAb
A0137-100ul	Abclonal	100 ul	EUR 369.6

TERF1 Rabbit pAb
A0137-200ul	Abclonal	200 ul	EUR 550.8

TERF1 Rabbit pAb
A0137-20ul	Abclonal	20 ul	EUR 219.6

TERF1 Rabbit pAb
A0137-50ul	Abclonal	50 ul	EUR 267.6

TERF2 Rabbit pAb
A0138-100ul	Abclonal	100 ul	EUR 460.8

TERF2 Rabbit pAb
A0138-200ul	Abclonal	200 ul	Ask for price

TERF2 Rabbit pAb
A0138-20ul	Abclonal	20 ul	Ask for price

TERF2 Rabbit pAb
A0138-50ul	Abclonal	50 ul	EUR 318

SPHK1 Rabbit pAb
A0139-100ul	Abclonal	100 ul	EUR 369.6

SPHK1 Rabbit pAb
A0139-200ul	Abclonal	200 ul	EUR 550.8

SPHK1 Rabbit pAb
A0139-20ul	Abclonal	20 ul	EUR 219.6

SPHK1 Rabbit pAb
A0139-50ul	Abclonal	50 ul	EUR 267.6

NCK1 Rabbit pAb
A0140-100ul	Abclonal	100 ul	EUR 369.6

NCK1 Rabbit pAb
A0140-200ul	Abclonal	200 ul	EUR 550.8

NCK1 Rabbit pAb
A0140-20ul	Abclonal	20 ul	Ask for price

NCK1 Rabbit pAb
A0140-50ul	Abclonal	50 ul	Ask for price

MAP2K2 Rabbit pAb
A0143-100ul	Abclonal	100 ul	EUR 369.6

MAP2K2 Rabbit pAb
A0143-200ul	Abclonal	200 ul	EUR 550.8

MAP2K2 Rabbit pAb
A0143-20ul	Abclonal	20 ul	Ask for price

MAP2K2 Rabbit pAb
A0143-50ul	Abclonal	50 ul	Ask for price

MAP2K6 Rabbit pAb
A0145-100ul	Abclonal	100 ul	EUR 369.6

MAP2K6 Rabbit pAb
A0145-200ul	Abclonal	200 ul	EUR 550.8

MAP2K6 Rabbit pAb
A0145-20ul	Abclonal	20 ul	Ask for price

MAP2K6 Rabbit pAb
A0145-50ul	Abclonal	50 ul	Ask for price

SLC9A3R1 Rabbit pAb
A0146-100ul	Abclonal	100 ul	EUR 369.6

SLC9A3R1 Rabbit pAb
A0146-200ul	Abclonal	200 ul	EUR 550.8

SLC9A3R1 Rabbit pAb
A0146-20ul	Abclonal	20 ul	EUR 219.6

SLC9A3R1 Rabbit pAb
A0146-50ul	Abclonal	50 ul	EUR 267.6

Bmi1 Rabbit pAb
A0147-100ul	Abclonal	100 ul	EUR 369.6

Bmi1 Rabbit pAb
A0147-200ul	Abclonal	200 ul	EUR 550.8

Bmi1 Rabbit pAb
A0147-20ul	Abclonal	20 ul	Ask for price

Bmi1 Rabbit pAb
A0147-50ul	Abclonal	50 ul	Ask for price

UCHL1 Rabbit pAb
A0148-100ul	Abclonal	100 ul	EUR 369.6

UCHL1 Rabbit pAb
A0148-200ul	Abclonal	200 ul	EUR 550.8

UCHL1 Rabbit pAb
A0148-20ul	Abclonal	20 ul	EUR 219.6

UCHL1 Rabbit pAb
A0148-50ul	Abclonal	50 ul	EUR 267.6

DCX Rabbit pAb
A0149-100ul	Abclonal	100 ul	EUR 369.6

DCX Rabbit pAb
A0149-200ul	Abclonal	200 ul	EUR 550.8

DCX Rabbit pAb
A0149-20ul	Abclonal	20 ul	Ask for price

DCX Rabbit pAb
A0149-50ul	Abclonal	50 ul	Ask for price

TRAF1 Rabbit pAb
A0150-100ul	Abclonal	100 ul	EUR 369.6

TRAF1 Rabbit pAb
A0150-200ul	Abclonal	200 ul	EUR 550.8

TRAF1 Rabbit pAb
A0150-20ul	Abclonal	20 ul	EUR 219.6

TRAF1 Rabbit pAb
A0150-50ul	Abclonal	50 ul	EUR 267.6

GNB2L1 Rabbit pAb
A0151-100ul	Abclonal	100 ul	EUR 369.6

GNB2L1 Rabbit pAb
A0151-200ul	Abclonal	200 ul	EUR 550.8

GNB2L1 Rabbit pAb
A0151-20ul	Abclonal	20 ul	EUR 219.6

GNB2L1 Rabbit pAb
A0151-50ul	Abclonal	50 ul	EUR 267.6

Macular structural characteristics on the limits and outside the lesions include intrarinal hyperreflective points, macular sistoid edema, subretinal fluid and loss of ellipsoid zone (EZ). Selective EZ losses found in 6 of 12 eyes showed recovery in 4 eyes after receiving anti-virus treatment. In the eye of CMVR, there are microvascular abnormalities and microstructure in the macular area without cmvr lesions that are clinically seen. Our results provide interesting insights into Retina CMV infection.